Neal Browning is a 46-year-old network engineer at Microsoft. He's also one of the first in the U.S. to receive an experimental COVID-19 vaccine from Moderna. “I felt like it was kind of my duty as a healthy individual to step up.'
This interview is the second in a series of conversations MarketWatch will conduct with some of the leading voices in the U.S. on the COVID-19 pandemic.
A handful of vaccine candidates who have entered the clinic in the U.S. reported interim results from the first phase of testing; however, Moderna, a preclinical biotechnology company based in Cambridge, Mass., was the first to do so. Eight of the trial’s 45 participants developed neutralizing antibodies, thought to be a key benchmark in creating a vaccine that will protect to some degree against future COVID-19 infections.
MarketWatch: That was a very intense week. That was when a lot of the formal lockdowns went into place in the U.S. I think it was right around time that Americans realized how serious this pandemic could be.MarketWatch: What was that like going into [the clinic] to get the shot on that day? MarketWatch: Has anything surprised you about the clinical trial process? Would you do it again knowing what you know now?
MarketWatch: Going through this experience, how has it shaped your worldview on the pandemic and the U.S. response?
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Canada signs deals with Pfizer, Moderna for experimental COVID-19 vaccinesCanada has signed separate deals with Pfizer Inc and Moderna Inc to supply millions of doses of their experimental coronavirus vaccines, a top official said on Wednesday.
Weiterlesen »
‘Will the public be ready for a vaccine?’ Many Americans say they won’t get the coronavirus vaccine if one is developedSurveys show people are divided along political and state lines about trusting a COVID-19 vaccine
Weiterlesen »
It's not for me: speed of COVID-19 vaccine race raises safety concernsThe frenetic race to develop a COVID-19 vaccine has intensified safety concerns about an inoculation, prompting governments and drugmakers to raise awareness to ensure their efforts to beat the coronavirus aren't derailed by public distrust.
Weiterlesen »
Prices For COVID-19 Vaccines Are Starting To Come Into FocusModerna, one of the leading horses in the coronavirus vaccine race, has already made deals at between $32 and $37 a dose for some foreign countries. The U.S. price is expected to be lower.
Weiterlesen »
CVS raises profit forecast, in talks with government to administer COVID-19 vaccinesDrugstore operator CVS Health Corp raised its full-year profit forecast on Wednesday and said it was in talks with the U.S. government to administer coronavirus vaccines at its pharmacies once they become available.
Weiterlesen »
Moderna says discussing supply deals with countries for COVID-19 vaccineModerna Inc is in talks with several countries for supply agreements for its experimental coronavirus vaccine, the company said on Wednesday, adding that it had already received about $400 million in deposits for potential supply.
Weiterlesen »